Search Results for 'nsclc'
nsclc published presentations and documents on DocSlides.
Antiangiogenic Agents in Advanced NSCLC
by ellena-manuel
Jared Weiss, MD . Assistant . Professor of Medici...
EGFR-Mutated Advanced NSCLC
by sherrill-nordquist
The Coming Paradigm Shift. Faculty. Suresh S. Ram...
Raising the Bar in the Management of Advanced/Metastatic NSCLC
by debby-jeon
Dr Tan . Jiunn. Liang. Clinical Specialist (Resp...
SW GLH services for NSCLC – An update
by everly
Professor Rachel Butler. The genomic complexity of...
NSCLC with high PD-L1 expression on tumor cells or tumor-infiltrating immune cells represents disti
by sawyer742
Intervista a Federico . Cappuzzo. Background:. Pr...
Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
by stefany-barnette
Renato G. Martins, MD, MPH. Medical Director, Tho...
Treatment in Advanced Non-Small Cell Lung Cancer
by oconnor
. 5. th. most commonly diagnosed cancer in Austra...
Multidisciplinary approach to lung cancer
by elena
Kamil Konopka. Department of Oncology, University ...
Beth Sandy, MSN, CRNP Nurse Practitioner
by PriceOfFreedom
Abramson Cancer Center . University of Pennsylvani...
NSCLC: Epidemiology and disease characteristics
by scarlett
NSCLC, non-small cell lung cancer.. Lung cancer in...
Please note, these are the actual video-recorded
by chaptoe
proceedings from the live CME event and may includ...
Optimizing Nursing Management of Patients Receiving Novel Therapies for Advanced NSCLC
by southan
Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Pra...
The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature
by stefany-barnette
The Cancer genome atlas (TCGA) and the search for...
EGFR-Mutated NSCLC and CNS Involvement: the Conundrum
by pasty-toler
This program will include a discussion of off-lab...
NSCLC with high PD-L1 expression on tumor cells or tumor-in
by test
Intervista a Federico . Cappuzzo. Background:. P...
Using Non-targeted Therapies in Targeted Lung Cancer Popula
by ellena-manuel
Nathan Pennell, M.D., Ph.D.. September 6, 2014. O...
MEK Inhibitors and their potential role in relapsed NSCLC
by debby-jeon
Ranee Mehra, MD. Fox Chase Cancer Center. Philade...
The Role of Antiangiogenic Agents
by luanne-stotts
The Role of Antiangiogenic Agents in the Changin...
Targeting KRAS G12C Â in Solid Tumors
by morton
: . A . New Anticancer Approach  . Marwan Fakih, ...
The Winship Cancer Institute of Emory University
by jalin
July 22, 2023. Adjuvant immunotherapy for resectab...
ALK in lung cancer: Past, present, and future
by belinda
Gene Mutations in Lung . Adenocarcinomas. 17 years...
AdjuvantTherapyforStageIandIINonSmallCellLungCancerEvanCNaylorPatie
by susan2
DisclosureStatement:Theauthorhasnothingtodisclose....
NonSmallCellLungCancerVersion32022DavidSEttingerMDDouglasEWoodM
by cecilia
NCCNCATEGORIESOFEVIDENCEANDCONSENSUSCategory1:Base...
cell lung cancer NSCLCESMO Clinical Practice Guidelines for diagnosi
by adia
RecommendationLoE, GoRScreening with LDCT (low-dos...
ALL, Acute lymphoblastic leukemia;
by HappyHippo
BCMA, B-cell maturation antigen; DLBCL, diffuse la...
iJOURNAL CLUB: Optimizing Therapy for Patients with Metastatic Squamous Cell Carcinoma of the Lung
by berey
Interview with Shirish M . Gadgeel. , MD . January...
Mechanisms of ALK Resistance & Implications for Treatment
by evans
Robert C. Doebele, MD, PhD. Associate Professor, ....
Updates in the systemic treatment for lung
by madeline
cancer: Immunotherapy. Oscar Arrieta MD. Thoracic....
FIRST-LINE EGFRm+ NSCLC PATIENT CASE STUDY
by pamela
Case study 9. Provided by . Dr Qamar Ghafoor, Clin...
CLINICAL EXPERIENCE OF NSCLC in RSDM
by sophia
Ana Rima. PENDAHULUAN. 2. Kanker Paru. P. enyebab ...